Fibrin

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Retrieved on: 
Wednesday, February 14, 2024

AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.

Key Points: 
  • AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
  • Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing.
  • “The positive results for Biotest’s fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” said Victor Grifols Deu, Grifols Chief Operating Officer.
  • The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence.

Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive Bleeding

Retrieved on: 
Wednesday, November 15, 2023

RARITAN, N.J., Nov. 15, 2023 /PRNewswire/ -- Ethicon*, a Johnson & Johnson MedTech company**, today announced the approval of ETHIZIA™, an adjunctive hemostat solution which has been clinically proven to achieve sustained hemostasis in difficult to control bleeding situations.1 Comprised of unique synthetic polymer technology, ETHIZIA™ Hemostatic Sealing Patch is the first and only hemostatic matrix designed to be equally active and efficacious on both sides***.2 Designed for maximum adaptability, it can be stuffed, rolled, pulled apart, trimmed and tailored,3, 4 making it easy to handle in both open and minimally invasive surgeries.5 In 80% of clinical trial patients studied****, ETHIZIA™ Hemostatic Sealing Patch stopped bleeding in 30 seconds, an average of six times faster than the leading Fibrin Sealant Patch*****.6 7

Key Points: 
  • "As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions," said Vladimir Makatsaria, Company Group Chairman, Ethicon.
  • "Disruptive bleeding can contribute to serious complications, and with the addition of ETHIZIA™ to our portfolio, we are well positioned to deliver critical hemostasis solutions for patients."
  • In May 2022, Ethicon acquired GATT Technologies B.V., a Netherlands-based company using differentiated synthetic polymer to create hemostatic and sealant products to address complex surgical bleeding and leak challenges.
  • As a global leader in surgery, Ethicon harnesses deep expertise to design surgical solutions that are smarter, less invasive, and more personalized.

Iteld Plastic Surgery Launches New Aesthetics Website

Retrieved on: 
Tuesday, October 31, 2023

The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.

Key Points: 
  • The Iteld Aesthetics Institute site, which launched this summer, includes detailed information on services such as PRP and PRF , PRF EZ Gel plasma filler, Sculptra® biostimulatory fillers , and microneedling with exosomes.
  • Patients who are seeking other types of surgical and non-surgical cosmetic procedures can find more details on various options on the main Iteld Plastic Surgery website.
  • For more information on natural non-surgical skin rejuvenation treatments, contact Chicago’s Iteld Plastic Surgery.
  • Call (312) 757-4505, fill out a contact form to schedule a consultation, or visit the Iteld Aesthetics Institute site for more details.

Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia

Retrieved on: 
Tuesday, October 24, 2023

SACRAMENTO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced interim results from the Phase 1 trial of its lead candidate, THN391, for the treatment of dementia. The data will be detailed in a poster presentation at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place from October 25-27, 2023, in Boston, MA.

Key Points: 
  • SACRAMENTO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced interim results from the Phase 1 trial of its lead candidate, THN391, for the treatment of dementia.
  • Vascular dysfunction is a key driver in many neurodegenerative diseases, with fibrin playing a major role.
  • THN391 is a potential first-in-class, therapeutic, monoclonal antibody that is designed to target the inflammatory properties of fibrin without disrupting coagulation and protective innate immunity.
  • Data from the first two cohorts, 0.3 mg/kg and 1.0 mg/kg, demonstrated a half-life of approximately 50 days in both groups.

Cresilon Announces Distribution Agreement for VETIGEL with Penn Veterinary Supply

Retrieved on: 
Tuesday, August 22, 2023

NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.

Key Points: 
  • NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.
  • VETIGEL is now available for veterinarians through Penn Veterinary Supply.
  • Cresilon's VETIGEL – a plant-based hemostatic gel that instantly stops and controls bleeding without the need to apply manual pressure – is now available for veterinarians through Penn Veterinary Supply .
  • Laura Williams, Penn Veterinary Supply, Director of Sales and Marketing commented; "Penn Veterinary Supply is excited to add VETIGEL to our portfolio of hemostatic technologies.

RedDress Receives Vizient Contract for Advanced Wound Care Solution ActiGraft PRO

Retrieved on: 
Tuesday, August 22, 2023

TEL AVIV, Israel and JACKSONVILLE, Fla., Aug. 22, 2023 /PRNewswire/ -- RedDress, developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, today announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company. RedDress secured an Innovative Technology contract with Vizient in October 2022 and G-Code reimbursement status from Medicare and Medicare Advantage in July 2023.

Key Points: 
  • Medicare and Medicare Advantage reimbursement status was recently obtained for ActiGraft PRO, enabling the wound care industry's most advanced whole-blood wound care solution to be purchased by wound care centers and practitioners nationally
    TEL AVIV, Israel and JACKSONVILLE, Fla., Aug. 22, 2023 /PRNewswire/ -- RedDress , developers of the ActiGraft PRO system, a personalized and autologous wound care solution created from patients' own whole blood, today announced that its ActiGraft PRO product is now available through Vizient, the nation's largest provider-driven healthcare performance improvement company.
  • "We are excited for the momentum we are experiencing since obtaining Medicare reimbursement status and are thrilled to make ActiGraft PRO now available to wound care specialists nationally through Vizient," said Alon Kushnir, CEO and Co-Founder of RedDress.
  • "Autologous, blood-based therapies are the future of wound care, and with ActiGraft PRO as the leading solution in the category, our contract with Vizient will significantly increase access to advanced wound care for patients and healthcare providers."
  • The ActiGraft PRO system is an autologous, point-of-care wound management solution created from patient's whole blood.

RedDress and OneMed form Strategic Partnership for the Commercialization and Distribution of the ActiGraft Wound Care System in the Nordics

Retrieved on: 
Tuesday, August 8, 2023

HELSINKI and TEL AVIV, Israel and JACKSONVILLE, Fla., Aug. 8, 2023 /PRNewswire/ -- RedDress, developers of the ActiGraft system, a personalized and autologous wound care solution created from patients own whole blood, today announced that it has established a strategic partnership with OneMed, part of the Asker Healthcare Group, to commercialize and distribute the ActiGraft system throughout Finland and Sweden. The multinational agreement is exclusive and follows an extensive product evaluation assessment.

Key Points: 
  • The wound care market in the Nordics is growing due to an aging population and the increased prevalence of chronic diseases.
  • The ActiGraft wound care system is an autologous, point-of-care wound management solution created from the patient's whole blood.
  • "We are very excited to announce this strategic partnership with OneMed to bring our leading chronic wound care solution to the Nordics", said Alon Kushnir, CEO and Co-Founder at RedDress.
  • We strongly believe that the ActiGraft wound care system will bring immense benefits for patients suffering from non-healing wounds, and an ease of treatment for care providers."

RedDress Launches ActiGraft PRO with G-Code Reimbursement Status for the US Wound Care Market

Retrieved on: 
Tuesday, July 18, 2023

TEL AVIV, Israel and JACKSONVILLE, Fla., July 18, 2023 /PRNewswire/ -- RedDress, a personalized and autologous wound care solution created from patients own whole blood, today announced that its ActiGraft PRO product is now commercially available throughout the US and is eligible for reimbursement nationally from Medicare and Medicare Advantage via NCD 270.3 and G-0465 & G-0460 codes. ActiGraft PRO is the most advanced whole-blood wound care solution on the market, offering a quick procedure time while eliminating the need for a centrifuge or a needle for blood transfer. Reimbursement for the procedure through Medicare and Medicare Advantage is $1726 per application for up to 20 applications in hospital outpatient facilities and wound care centers.

Key Points: 
  • ActiGraft PRO is the most advanced whole-blood wound care solution on the market, offering a quick procedure time while eliminating the need for a centrifuge or a needle for blood transfer.
  • Reimbursement for the procedure through Medicare and Medicare Advantage is $1726 per application for up to 20 applications in hospital outpatient facilities and wound care centers.
  • "Launching ActiGraft PRO, our most advanced wound care product, along with Medicare reimbursement status for patients across the US, is a significant milestone for us as a company and for the national wound care market as a whole", said Alon Kushnir, CEO and co-founder of RedDress.
  • The ActiGraft PRO system is an autologous, point-of-care wound management solution created from patient's whole blood.

Global Von Willebrand Disease (VWD) Treatment Market Report 2023: Increasing Public Awareness Related to VWD Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 12, 2023

On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.

Key Points: 
  • On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.
  • The types of therapeutic treatments used against von Willebrand disease are Desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing drugs, and fibrin sealants.
  • The key factor responsible for growth of von Willebrand disease is increasing public awareness related to VWD which is fueling the diagnosis rate in North America and Europe.
  • North America was observed as the largest market for von Willebrand disease treatment followed by Europe.

Revealing How Blood Triggers Brain Disease

Retrieved on: 
Thursday, June 8, 2023

SAN FRANCISCO, June 8, 2023 /PRNewswire/ -- In patients with neurological diseases like Alzheimer's disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment. These harmful immune cells may also contribute to age-related cognitive decline in people without dementia.

Key Points: 
  • The scientists discovered that a blood protein called fibrin—which normally aids blood clotting—is responsible for turning on the detrimental genes in microglia, both in Alzheimer's disease and multiple sclerosis.
  • Individuals with neurological diseases like Alzheimer's disease and multiple sclerosis have abnormalities within the vast network of blood vessels in their brain, which allow blood proteins to seep into brain areas responsible for cognitive and motor functions.
  • "These exciting findings change the way we think about blood proteins, from secondary bystanders to primary drivers of harm in the brain," says Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease.
  • "The mechanisms identified in this study could be at work in a range of neurological conditions involving blood leaks in the brain, including neurodegenerative disorders, autoimmune diseases, stroke, and traumatic brain injury.